Frontiers in Medicine (May 2022)
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
- Ennio Giulio Favalli,
- Ennio Giulio Favalli,
- Andrea Gobbini,
- Mauro Bombaci,
- Gabriella Maioli,
- Gabriella Maioli,
- Martina Biggioggero,
- Elisa Pesce,
- Andrea Favalli,
- Martina Martinovic,
- Tanya Fabbris,
- Edoardo Marchisio,
- Alessandra Bandera,
- Alessandra Bandera,
- Alessandra Bandera,
- Andrea Gori,
- Andrea Gori,
- Andrea Gori,
- Sergio Abrignani,
- Renata Grifantini,
- Roberto Caporali,
- Roberto Caporali
Affiliations
- Ennio Giulio Favalli
- Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy
- Ennio Giulio Favalli
- Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy
- Andrea Gobbini
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Mauro Bombaci
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Gabriella Maioli
- Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy
- Gabriella Maioli
- Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy
- Martina Biggioggero
- Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy
- Elisa Pesce
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Andrea Favalli
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Martina Martinovic
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Tanya Fabbris
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Edoardo Marchisio
- Dia.Pro, Diagnostic Bioprobes Srl, Milan, Italy
- Alessandra Bandera
- Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Alessandra Bandera
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
- Alessandra Bandera
- Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy
- Andrea Gori
- Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Andrea Gori
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
- Andrea Gori
- Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy
- Sergio Abrignani
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Renata Grifantini
- Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy
- Roberto Caporali
- Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy
- Roberto Caporali
- Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy
- DOI
- https://doi.org/10.3389/fmed.2022.923790
- Journal volume & issue
-
Vol. 9
Abstract
No abstracts available.Keywords
- seroprevalence
- SARS-CoV-2
- humoral response
- rheumatic musculoskeletal diseases
- disease-modifying anti-rheumatic drugs
- risk of infection
